Entera Bio Ltd. has released its financial results for the second quarter of 2025, reporting a net loss of $2.7 million, or $0.06 per ordinary share, compared to a net loss of $2.1 million, or $0.06 per ordinary share, for the same period in 2024. Research and development expenses increased to $1.5 million from $1.1 million in the corresponding 2024 period, largely due to regulatory activities and planning for the Phase 3 trial of EB613. General and administrative expenses remained steady at $1.1 million. Total operating expenses for the quarter were $2.7 million, up from $2.2 million in the prior year period. The company highlighted significant advancements in its pipeline and regulatory progress, including an FDA agreement on using Bone Mineral Density as the primary endpoint for the Phase 3 trial of EB613, which aims to become the first oral anabolic osteoporosis treatment. Entera Bio also reported promising preclinical data from its obesity program in collaboration with OPKO and candidate validation for its EB612 oral PTH program for hypoparathyroidism. The company's cash and cash equivalents stood at $18.9 million as of June 30, 2025, with a financial runway expected to sustain operations through mid-third quarter 2026.